A newly discovered immune cell “soldier” may be the next target for immunotherapy. Termed killer innate-like T cells, these cells are unlike the traditional targets of immunotherapies, that is they exhaust at a slower rate and penetrate more deeply into the tissue. Killer innate-like T cells can recognize unmutated antigens and are not dependent on antigen-presenting cells. Instead the cells are constantly primed, ready to attack cancerous cells. Researchers hope these T cells, as compared to conventional T cells, may help in eliciting immune response in patients unresponsive to immunotherapy treatment.